Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism

Journal of Neuroscience

Volumn 30, Issue 16, 2010, Pages 5525-5532

  Trinh, Kien ^a   Andrews, Laurie ^a   Krause, James ^a   Hanak, Tyler ^b   Lee, Daewoo ^b   Gelb, Michael ^a   Pallanck, Leo ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CAFESTOL; GALACTOSIDASE; GLUTATHIONE TRANSFERASE; GREEN FLUORESCENT PROTEIN; POLYGLUTAMINE; TRANSCRIPTION FACTOR NRF2; TYROSINE 3 MONOOXYGENASE;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CELL PROTECTION; COFFEE; CORRELATION ANALYSIS; DECAFFEINATED COFFEE; DOPAMINERGIC NERVE CELL; DROSOPHILA; IMMUNOHISTOCHEMISTRY; LIFESPAN; NEUROPROTECTION; NICOTINE FREE TOBACCO; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; TOBACCO;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAFFEINE; CELLS, CULTURED; COFFEE; DISEASE MODELS, ANIMAL; DITERPENES; DROSOPHILA; DROSOPHILA PROTEINS; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; NICOTINE; PARKINSON DISEASE; PLANT EXTRACTS; TOBACCO;

EID: 77951543964     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4777-09.2010     Document Type: Article

References (31)

1. Arias-Carrion O, Poppel E (2007) Dopamine, learning, and reward-seeking behavior. Acta Neurobiol Exp (Wars) 67:481-488.
2. Biskup S, Gerlach M, Kupsch A, Reichmann H, Riederer P, Vieregge P, Wullner U, Gasser T (2008) Genes associated with Parkinson syndrome. J Neurol 255 [Suppl 5]:S8-S17.
3. Brand AH, Perrimon N (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118:401-415.
4. Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B (2002) Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol 40:1155-1163. (Pubitemid 34626880)
5. Cavin C, Bezencon C, Guignard G, Schilter B (2003) Coffee diterpenes prevent benzo[a]pyrene genotoxicity in rat and human culture systems. Biochem Biophys Res Commun 306:488-495. (Pubitemid 36683100)
6. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5:525-535.
7. Dinkova-Kostova AT, Talalay P (2008) Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol Nutr Food Res 52 [Suppl 1]:S128-S138.
8. Eggler AL, Gay KA, Mesecar AD (2008) Molecular mechanisms of natural products in chemoprevention: induction of cytoprotective enzymes by Nrf2. Mol Nutr Food Res 52 [Suppl 1]:S84-S94.
9. Elbaz A, Tranchant C (2007) Epidemiologic studies of environmental exposures in Parkinson's disease. J Neurol Sci 262:37-44. (Pubitemid 47398893)
10. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M (2009) Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis 16:85-91.
11. Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M (2004) A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci 26:365-375.
12. Friggi-Grelin F, Coulom H, Meller M, Gomez D, Hirsh J, Birman S (2003) Targeted gene expression in Drosophila dopaminergic cells using regulatory sequences from tyrosine hydroxylase. J Neurobiol 54:618-627.
13. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A 100:4078-4083.
14. Hwang YP, Jeong HG (2008) The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Lett 582:2655-2662.
15. Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y (2004) Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc Natl Acad Sci U S A 101:6623-6628.
16. 2A receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 248:9-15.
17. Mizuno Y, Hattori N, Kubo S, Sato S, Nishioka K, Hatano T, Tomiyama H, Funayama M, Machida Y, Mochizuki H (2008) Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci 363:2215-2227. (Pubitemid 351693531)
18. O'Reilly EJ, McCullough ML, Chao A, Henley SJ, Calle EE, Thun MJ, Ascherio A (2005) Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord 20:1383-1384. (Pubitemid 41645921)
19. Park SS, LeeD (2006) Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures. Eur J Neurosci 23:2908-2914.
20. Park SS, Schulz EM, Lee D (2007) Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein. Eur J Neurosci 26:3104-3112.
21. Quik M, O'Leary K, Tanner CM (2008) Nicotine and Parkinson's disease: implications for therapy. Mov Disord 23:1641-1652.
22. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, Ross GW,Strickland D, Van Den Eeden SK, Gorell J (2007) Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 64:990-997. (Pubitemid 47047999)
23. Ross GW, Petrovitch H (2001) Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 18:797-806.
24. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29: 647-654. (Pubitemid 44602262)
25. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD (2000) Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 284:311-318. (Pubitemid 30469857)
26. Sykiotis GP, Bohmann D (2008) Keap1/Nrf2 signaling regulates oxidative stress tolerance and lifespan in Drosophila. Dev Cell 14:76-85.
27. Trinh K, Moore K, Wes PD, Muchowski PJ, Dey J, Andrews L, Pallanck LJ (2008) Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J Neurosci 28:465-472.
28. van Cruchten ST, de Waart R, Kunne C, Hooiveld GJ, Boekschoten MV, Katan MB, Oude Elferink RP, Witkamp RF (2010) Absorption, distribution and biliary excretion of cafestol, a potent cholesterol elevating compound in unfiltered coffees in mice. Drug Metab Dispos 38:635-640.
29. Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, Pittman RN, Bonini NM (1998) Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93:939-949.
30. Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, Pallanck LJ (2005) Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci U S A 102:8024-8029.
31. Yates MS, Kensler TW (2007) Chemopreventive promise of targeting the Nrf2 pathway. Drug News Perspect 20:109-117.